A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Arhalofenate (MBX-102) in Combination With Febuxostat for the Treatment of Hyperuricemia in Patients With Gout.
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2015
At a glance
- Drugs Arhalofenate; Febuxostat
- Indications Gout
- Focus Therapeutic Use
- Sponsors CymaBay Therapeutics
- 08 Dec 2011 Results have been reported in a Metabolex media release.
- 08 Dec 2011 Primary endpoint 'Response-rate' has been met.
- 20 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.